Emergent BioSolutions IncEBS:NYQ

43.56
0.41 / 0.95%
245.22k
40.43%
1.23
Latest price in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 27 2016 20:49 BST.

Summary

Emergent BioSolutions Inc (EBS:NYQ) set a new 52-week high during today's trading session when it reached 43.65. Over this period, the share price is up 36.72%.

52-week range
Today
27.68
Oct 07 2015
43.65
May 27 2016
Markit short selling activity
Low
Medium
High
Open43.13
Day high43.65
Day low42.81
Bid43.54
Offer43.57
Previous close43.15
Average volume533.86k
Shares outstanding40.06m
Free float32.26m
P/E (TTM)22.94
Market cap1.70bn USD
EPS (TTM)1.85 USD
Data delayed at least 15 minutes, as of May 27 2016 20:49 BST.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Emergent BioSolutions Inc+3.54 %+9.89 %+12.79 %+40.43 %+76.43 %
S&P 500 INDEX+1.84 %-0.24 %0.00%-1.57 %+57.02 %
USA/HEALTH CARE+1.63 %-0.75 %-2.33 %-7.14 %+49.90 %
USA/BIOTECHNOLOGY+3.57 %-2.89 %-13.24 %-19.57 %+68.48 %
Data delayed at least 15 minutes, as of May 27 2016 20:49 BST.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.